NYSEAMERICAN:AIM AIM ImmunoTech (AIM) Stock Price, News & Analysis $0.18 -0.01 (-4.10%) Closing price 04:10 PM EasternExtended Trading$0.18 0.00 (-1.67%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About AIM ImmunoTech Stock (NYSEAMERICAN:AIM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AIM ImmunoTech alerts:Sign Up Key Stats Today's Range$0.18▼$0.1950-Day Range$0.17▼$0.2952-Week Range$0.17▼$2.88Volume1.28 million shsAverage Volume12.19 million shsMarket Capitalization$5.48 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingModerate Buy Company Overview AIM ImmunoTech Inc. is a biotechnology company focused on developing and commercializing immunomodulatory therapies for cancer, viral diseases and disorders involving the immune system. The company’s lead product candidate is Ampligen (rintatolimod), an investigational double-stranded RNA therapeutic designed to stimulate immune responses and is being studied in several disease settings. AIM also owns Alferon N Injection, an interferon alfa-n3 product approved in the United States for the treatment of refractory or recurring external genital warts in adults. The company has explored additional applications for its therapies, including potential use against infectious diseases and cancers, through clinical research and collaborations. The company was formerly known as Hemispherx Biopharma Inc. and adopted the name AIM ImmunoTech in 2019. Its corporate headquarters are in Ocala, Florida, and its programs are primarily directed toward the U.S. market while also involving international research and development activities. Thomas K. Equels serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More AIM ImmunoTech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreAIM MarketRank™: AIM ImmunoTech scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAIM ImmunoTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialAIM ImmunoTech has a consensus price target of $9.00, representing about 4,900.0% upside from its current price of $0.18.Amount of Analyst CoverageAIM ImmunoTech has received no research coverage in the past 90 days.Read more about AIM ImmunoTech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AIM ImmunoTech are expected to grow in the coming year, from ($0.78) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AIM ImmunoTech is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AIM ImmunoTech is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.17% of the float of AIM ImmunoTech has been sold short.Short Interest Ratio / Days to CoverAIM ImmunoTech has a short interest ratio ("days to cover") of 0.25, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AIM ImmunoTech has recently increased by 382.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAIM ImmunoTech does not currently pay a dividend.Dividend GrowthAIM ImmunoTech does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.24 News SentimentAIM ImmunoTech has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for AIM ImmunoTech this week, compared to 3 articles on an average week.Search InterestOnly 13 people have searched for AIM on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.MarketBeat Follows3 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $13,488.00 in company stock, which represents 0.2462% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, AIM ImmunoTech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $13,488.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders0.95% of the stock of AIM ImmunoTech is held by insiders.Percentage Held by Institutions12.02% of the stock of AIM ImmunoTech is held by institutions.Read more about AIM ImmunoTech's insider trading history. Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AIM Stock News HeadlinesAIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline DataOctober 1 at 9:02 AM | globenewswire.comAIM ImmunoTech Inc. Releases New CEO Corner Segment Discussing Ampligen?s Potential To Complement Emerging Pancreatic Cancer TherapiesOctober 1 at 1:49 AM | marketscreener.comMIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.October 2 at 1:00 AM | Banyan Hill Publishing (Ad)Ionic Rare Earths targets AIM listing as Belfast magnet recycling strategy gathers paceSeptember 30 at 9:00 PM | proactiveinvestors.comAIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner VideoSeptember 30 at 11:49 AM | markets.businessinsider.comAIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner VideoSeptember 30 at 8:44 AM | globenewswire.comOndine Biomedical pauses trading to raise fresh investment after positive phase III resultSeptember 30 at 4:00 AM | proactiveinvestors.comAIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Shares Shorted: Short Interest Up 382.9% in SeptemberSeptember 27, 2026 | americanbankingnews.comSee More Headlines AIM Stock Analysis - Frequently Asked Questions How have AIM shares performed this year? AIM ImmunoTech's stock was trading at $1.1289 at the start of the year. Since then, AIM stock has decreased by 84.1% and is now trading at $0.18. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) issued its quarterly earnings results on Friday, August, 7th. The company reported ($0.43) earnings per share for the quarter. The company earned $0.03 million during the quarter. When did AIM ImmunoTech's stock split? AIM ImmunoTech shares reverse split before market open on Thursday, June 12th 2025.The 1-100 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Gold Resource (GORO), 36Kr (KRKR), Ocean Power Technologies (OPTT), Aemetis (AMTX), Avino Silver & Gold Mines (ASM), eMagin (EMAN) and EMX Royalty (EMX). Company Calendar Last Earnings8/07/2026Today10/02/2026AGM 202611/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:AIM Previous SymbolNYSEAMERICAN:HEB CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees21Year Founded1990Price Target and Rating Average Price Target for AIM ImmunoTech$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside+4,900.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($24.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.96 million Net Margins-15,021.05% Pretax Margin-15,021.05% Return on EquityN/A Return on Assets-143.02% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual Sales$90 thousand Price / Sales60.88 Cash FlowN/A Price / Cash FlowN/A Book Value($2.99) per share Price / Book-0.06Miscellaneous Outstanding Shares30,440,000Free Float30,153,000Market Cap$5.48 million OptionableNot Optionable Beta1.27 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSEAMERICAN:AIM) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
